Moreover, the use of pharmacological therapies, and especially of GLP-1 receptor agonists, for the treatment of diabetes and obesity can influence eating behaviors [47]; this aspect needs further clarification to also assess clinical efficacy on the psychopathology pathway of the various eating behaviors. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.